Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Escalation of Abiraterone Acetate Guided by Plasma Levels in Progressive Metastatic Castration-Resistant Prostate Cancer
2017-000560-15Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abiraterone in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Non-progression rate at 12 weeks. Started Jan 2018; status: completed.
02
Drugs
abiraterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2017-000560-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000560-15.